Procurement & Data Management Intern

Revvity to acquire Human Cell Design to advance human-relevant cell models for metabolic disease drug discovery. Waltham, MA (BUSINESS WIRE) - Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD's human pancreatic beta cell models to Revvity's Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including applications in GLP-1 and other metabolic disease therapies. The transaction is expected to close in Q4 2026 and is subject to customary closing conditions, including required regulatory approvals. Additional terms of the transaction were not disclosed. "HCD brings differentiated human cell models that complement Revvity's broad portfolio of technologies supporting drug discovery and development," said Prahlad Singh, president and CEO of Revvity. "As researchers continue to seek more human-relevant approaches to understanding biology, combining high-quality cell models with our capabilities in screening, detection, automation and analysis creates an opportunity to provide customers with more integrated solutions." HCD's flagship EndoC-βH5 human pancreatic beta cell model is designed to provide researchers with a human-relevant model for studying beta cell physiology and function across diabetes and obesity research. HCD also offers specialized media and reagents, preclinical research, and its proprietary NatLine cell-line development platform, which supports the development of functionally consistent human cell models. "Human Cell Design was founded on the belief that better human models can help transform the way medicines are discovered and developed," said Guillaume Costecalde, founder and president of Human Cell Design. "Joining Revvity is expected to allow us to bring our human cell models and NatLine technology to a broader global customer base while supporting the development of new physiologically relevant cell models." The combination aligns with Revvity's portfolio of detection and cell analysis technologies. EndoC-βH5 cells are well-suited for use with Revvity's HTRF(TM) and AlphaLISA(TM) assays for measuring key pharmacological readouts such as cAMP and insulin as well as pHSense(TM) technology for receptor internalization studies. The combination also extends to Revvity's ATPlite(TM) assays for cell viability and proliferation analysis. These detection and analysis capabilities are expected to extend to Revvity's high-content screening platform and increasingly sophisticated approaches to interpreting complex cellular data. As wet-lab validation becomes increasingly important to support AI-enhanced science, human-relevant cell models provide an important foundation for testing and confirming AI-generated insights. HCD's technology also has applications beyond early-stage discovery, including research supporting regenerative medicine approaches for Type 1 diabetes and quality control activities as cell-based therapies progress toward commercialization. Upon completion of the acquisition, the combined solutions are expected to create an opportunity to support customers across multiple stages of therapeutic research and development. Factors Affecting Future Performance This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes", "intends", "anticipates", "plans", "expects", "estimates", "projects", "forecasts", "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments, including as the result of recently implemented and recently threatened tariff increases; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and divestitures, such as the acquisition of HCD, license technologies, or to successfully integrate acquired businesses or licensed technologies into our existing businesses or to make them profitable; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (8) disruptions in the supply of raw materials and supplies; (9) our ability to retain key personnel; (10) significant disruption in our information technology systems, or cybercrime; (11) uncertainties related to the development and use of AI in our product offerings and internal operations; (12) our ability to realize the full value of our intangible assets; (13) our failure to adequately protect our intellectual property; (14) the loss of any of our licenses or licensed rights; (15) the manufacture and sale of products exposing us to product liability claims; (16) our failure to maintain compliance with applicable government regulations; (17) our failure to comply with data privacy and information security laws and regulations; (18) regulatory changes; (19) our failure to comply with healthcare industry regulations; (20) economic, political and other risks associated with foreign operations; (21) our ability to obtain future financing; (22) restrictions in our credit agreements; (23) significant fluctuations in our stock price; (24) reduction or elimination of dividends on our common stock; and (25) other factors which we describe under the caption "Risk Factors" in its most recent quarterly report on Form 10-Q and in its other filings with the Securities and Exchange Commission. Drug Discovery Online disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries. (C) 2026 Business Wire, Inc.

Revvity to acquire Human Cell Design to advance human-relevant cell models for metabolic disease drug discovery. Published at September 9th 2026, 6:00 AM EDT via Business Wire i This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. * Acquisition strengthens Revvity's position in human-relevant life sciences tools for next-generation GLP-1 and GPCR-targeting therapies for metabolic drug discovery * Combines HCD's human pancreatic beta cell models with Revvity's capabilities in cell analysis, detection, high-content screening and gene editing * Expands Revvity's ability to support customers across the research-to-clinic continuum, including emerging applications in clinical development and regenerative medicine Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD's human pancreatic beta cell models to Revvity's Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including applications in GLP-1 and other metabolic disease therapies. The transaction is expected to close in Q4 2026 and is subject to customary closing conditions, including required regulatory approvals. Additional terms of the transaction were not disclosed. Pharmaceuticals & Biotech "HCD brings differentiated human cell models that complement Revvity's broad portfolio of technologies supporting drug discovery and development," said Prahlad Singh, president and CEO of Revvity. "As researchers continue to seek more human-relevant approaches to understanding biology, combining high-quality cell models with our capabilities in screening, detection, automation and analysis creates an opportunity to provide customers with more integrated solutions." HCD's flagship EndoC-βH5 human pancreatic beta cell model is designed to provide researchers with a human-relevant model for studying beta cell physiology and function across diabetes and obesity research. HCD also offers specialized media and reagents, preclinical research, and its proprietary NatLine cell-line development platform, which supports the development of functionally consistent human cell models. "Human Cell Design was founded on the belief that better human models can help transform the way medicines are discovered and developed," said Guillaume Costecalde, founder and president of Human Cell Design. "Joining Revvity is expected to allow us to bring our human cell models and NatLine technology to a broader global customer base while supporting the development of new physiologically relevant cell models." The combination aligns with Revvity's portfolio of detection and cell analysis technologies. EndoC-βH5 cells are well-suited for use with Revvity's HTRF(TM) and AlphaLISA(TM) assays for measuring key pharmacological readouts such as cAMP and insulin as well as pHSense(TM) technology for receptor internalization studies. The combination also extends to Revvity's ATPlite(TM) assays for cell viability and proliferation analysis. These detection and analysis capabilities are expected to extend to Revvity's high-content screening platform and increasingly sophisticated approaches to interpreting complex cellular data. As wet-lab validation becomes increasingly important to support AI-enhanced science, human-relevant cell models provide an important foundation for testing and confirming AI-generated insights. HCD's technology also has applications beyond early-stage discovery, including research supporting regenerative medicine approaches for Type 1 diabetes and quality control activities as cell-based therapies progress toward commercialization. Upon completion of the acquisition, the combined solutions are expected to create an opportunity to support customers across multiple stages of therapeutic research and development. Factors Affecting Future Performance This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes", "intends", "anticipates", "plans", "expects", "estimates", "projects", "forecasts", "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments, including as the result of recently implemented and recently threatened tariff increases; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and divestitures, such as the acquisition of HCD, license technologies, or to successfully integrate acquired businesses or licensed technologies into our existing businesses or to make them profitable; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (8) disruptions in the supply of raw materials and supplies; (9) our ability to retain key personnel; (10) significant disruption in our information technology systems, or cybercrime; (11) uncertainties related to the development and use of AI in our product offerings and internal operations; (12) our ability to realize the full value of our intangible assets; (13) our failure to adequately protect our intellectual property; (14) the loss of any of our licenses or licensed rights; (15) the manufacture and sale of products exposing us to product liability claims; (16) our failure to maintain compliance with applicable government regulations; (17) our failure to comply with data privacy and information security laws and regulations; (18) regulatory changes; (19) our failure to comply with healthcare industry regulations; (20) economic, political and other risks associated with foreign operations; (21) our ability to obtain future financing; (22) restrictions in our credit agreements; (23) significant fluctuations in our stock price; (24) reduction or elimination of dividends on our common stock; and (25) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. Stocks & Bonds About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries. Revvity has entered into an agreement to acquire Human Cell Design (HCD), a biotechnology company developing human-relevant cell models for diabetes, obesity and other metabolic diseases. Contacts. Investor Relations: Steve Willoughby [email protected] Media Relations: Chet Murray (781) 462-5126 [email protected] Report this content If you believe this article contains misleading, harmful, or spam content, please let us know.

Finland bets on a category the World has underfunded: Over 300 founders answer the call for Women's Health. 02.09.2026 Eir Accelerator's first international cohort will connect women's health startups with Finnish and international clinical, research and life-sciences expertise, alongside a global investor and industry network. Over 300 founders from around the world have applied to Eir Accelerator, a new six-month international accelerator for women's health startups. Applications closed on 31 August, with 304 submissions from 53 countries highlighting an incredible global interest in the program. Europe and North America represented the strongest regions of interest. The response comes as women's health moves rapidly up the global innovation agenda. Despite growing recognition of the unmet need, many conditions affecting women remain under-researched, underdiagnosed and poorly served by existing treatments. The challenge is increasingly moving beyond awareness: founders, investors, healthcare systems and governments are now building the infrastructure needed to turn women's health research into products and care. PwC estimates the global women's health market will reach $600 billion by 2030, with a broader definition (including cardiovascular disease, autoimmune disorders, and mental health) putting today's market at roughly $430-440 billion; within that, "core" segments like fertility, maternal health, gynecological conditions, menopause and women's oncology account for about $195-205 billion today, rising to $270-280 billion by 2030. Eir Accelerator is designed around that gap. Rather than focusing on capital alone, it connects international founders with clinical expertise, research infrastructure, regulatory knowledge, industry partners and routes into healthcare markets. Finland's life sciences ecosystem provides a launchpad. Finland offers a strong foundation for this approach. Turku is one of the country's leading life-sciences clusters, bringing together pharmaceutical and diagnostics companies, universities, healthcare providers and research infrastructure. Eir Accelerator, named after the Norse goddess of healing, launched publicly in May 2026 and is run in partnership with Women's Health Hub Finland, a network of more than 25 pharmaceutical, diagnostics, research and public-sector organizations. Its first cohort begins on 18 November 2026, with the launch taking place alongside the Slush technology conference in Helsinki. Over six months, selected startups receive full funding and hands-on support across clinical evidence generation, European and U.S. regulatory pathways, commercialization and partnerships. The programme is open to early-stage companies working across reproductive health, endometriosis, menopause, maternal health and AI applications in women's health. Founders from Finland, the Nordics, wider Europe and beyond are eligible to participate. - Women's health is becoming an increasingly important area of innovation globally, and Finland has many of the ingredients needed to play a meaningful role - strong healthcare and research infrastructure, a life-sciences ecosystem and a growing focus on women's health, said Minna Arve, CEO of Business Turku, which coordinates the programme. - Eir is designed to connect those strengths with international founders and help build the partnerships needed to turn promising ideas into solutions that can reach patients, Arve continues. - Accelerators typically take years to build this kind of application volume - Business Turku did it in a matter of months, said Anastasiya Markvarde, Head of Eir Accelerator. - Over 300 applications, including strong markets such as the US and the UK, tell Business Turku founders worldwide are actively looking for a place like this to exist. Finland has the healthcare system, the industry base and the ambition to be that place. A network connecting startups, industry and investors. Eir's partner network includes pharmaceutical and life-sciences companies Bayer, Orion, Revvity and Organon, alongside the University of Turku, BioInnovation Institute and New Children's Hospital Foundation. Startups will also gain access to an international investor network including Innovestor, Inventure and Voima Ventures in Finland, and Angelini Ventures and Panakes Partners in Italy, Calm/Storm in Austria, Heal Capital in Germany, Verge HealthTech in Singapore and Suncoast Ventures in the U.S. Jessica Federer, former Chief Digital Officer of Bayer AG and founder of The Women's Health Fund, is among the programme's advisors. The cohort is deliberately focused on women's health rather than general health technology. Companies span different stages of development, from research- and preclinical-stage biotech to technologies approaching clinical validation and market entry. This allows Eir to connect startups with different parts of Finland's ecosystem depending on their needs - from research and clinical expertise to validation, partnerships and future market access. The economic cost of the Women's Health gap. The response comes as the economic cost of the women's health gap draws increasing attention worldwide. Just nine health conditions - including ischemic heart disease, breast cancer, maternal hypertensive disorder and menopause - drive more than a third of the global women's health burden, and closing that gap for those conditions alone could add nearly $400 billion to global GDP annually by 2040, according to the World Economic Forum and McKinsey Health Institute. Eir Accelerator, together with Suncoast Ventures, is currently completing a first-of-its-kind cost-of-illness study quantifying the annual economic burden of women's health conditions specifically for Finland, modelling fifty conditions across the female population. The findings will be released in the coming weeks. Eir Accelerator's selection committee is now reviewing applications. The first cohort will be announced ahead of the programme's launch on 18 November 2026 at Slush in Helsinki. Updates on the selection process and final cohort: eir-accelerator.com About Eir Accelerator. Eir Accelerator is a free six-month international accelerator positioning Finland as a global hub for women's health innovation. Coordinated by Business Turku in partnership with Women's Health Hub Finland, the program supports early-stage founders in generating clinical evidence, navigating European and U.S. regulatory requirements, and building partnerships with pharmaceutical, hospital and technology partners. Its first cohort kicks off 16 November 2026 in Helsinki. eir-accelerator.com Inquiries. About Business Turku. Business Turku is the economic development organization for the City of Turku, Finland, supporting business growth, investment and innovation across the region. First in business since 1229, Business Turku works with startups, established companies and international partners across life sciences, technology and other key sectors. businessturku.fi